Bank Pictet & Cie Europe AG Sells 523,696 Shares of Boston Scientific Corporation $BSX

Bank Pictet & Cie Europe AG cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 72.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 194,277 shares of the medical equipment provider’s stock after selling 523,696 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Boston Scientific were worth $8,480,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Perigon Wealth Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd grew its position in Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after acquiring an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC bought a new position in Boston Scientific in the second quarter valued at $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after acquiring an additional 28,961 shares during the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in Boston Scientific during the second quarter valued at about $38,539,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 0.3%

Shares of Boston Scientific stock traded up $0.15 during trading on Tuesday, reaching $45.20. 7,378,052 shares of the stock were exchanged, compared to its average volume of 18,504,900. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market cap of $65.51 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 1.07 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $41.38 and a 1 year high of $105.65. The stock’s fifty day moving average is $45.95 and its 200 day moving average is $49.54.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. Evercore decreased their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a report on Wednesday, October 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Citigroup cut their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. Finally, Mizuho set a $55.00 price target on shares of Boston Scientific in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $68.23.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.